The coming decade in precision oncology: six riddles.
Journal
Nature reviews. Cancer
ISSN: 1474-1768
Titre abrégé: Nat Rev Cancer
Pays: England
ID NLM: 101124168
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
accepted:
14
10
2022
pubmed:
27
11
2022
medline:
27
12
2022
entrez:
26
11
2022
Statut:
ppublish
Résumé
High-throughput methods to investigate tumour omic landscapes have quickly catapulted cancer specialists into the precision oncology era. The singular lesson of precision oncology might be that, for it to be precise, treatment must be personalized, as each cancer's complex molecular and immune landscape differs from patient to patient. Transformative therapies include those that are targeted at the sequelae of molecular abnormalities or at immune mechanisms, and, increasingly, pathways previously thought to be undruggable have become druggable. Critical to applying precision medicine is the concept that the right combination of drugs must be chosen for each patient and used at the right stage of the disease. Multiple puzzles remain that complicate therapy choice, including evidence that deleterious mutations are common in normal tissues and non-malignant conditions. The host's role is also likely to be key in determining treatment response, especially for immunotherapy. Indeed, maximizing the impact of immunotherapy will require omic analyses to match the right immune-targeted drugs to the individualized patient and tumour setting. In this Perspective, we discuss six key riddles that must be solved to optimize the application of precision oncology to otherwise lethal malignancies.
Identifiants
pubmed: 36434139
doi: 10.1038/s41568-022-00529-3
pii: 10.1038/s41568-022-00529-3
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
43-54Informations de copyright
© 2022. Springer Nature Limited.
Références
Christie, A. Peril at End House (Collins Crime Club, 1932).
Strebhardt, K. & Ullrich, A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8, 473–480 (2008).
doi: 10.1038/nrc2394
Ehrlich, P. Experimental researches on specific therapeutics. Am. J. Med. Sci. 139, 432 (1910).
doi: 10.1097/00000441-191003000-00018
Venter, J. C. et al. The sequence of the human genome. Science 291, 1304–1351 (2001).
doi: 10.1126/science.1058040
Lander, E. S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860–921 (2001).
doi: 10.1038/35057062
Wetterstrand, K. A. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP). Genome.gov https://www.genome.gov/about-genomics/fact-sheets/DNA-Sequencing-Costs-Data (2019).
Bower, H. et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J. Clin. Oncol. 34, 2851–2857 (2016).
doi: 10.1200/JCO.2015.66.2866
Westin, J. R. & Kurzrock, R. It’s about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol. Cancer Ther. 11, 2549–2555 (2012).
doi: 10.1158/1535-7163.MCT-12-0473
Hungerford, D. A. & Nowell, P. C. A minute chromosome in human chronic granulocytic leukemia. Science 132, 1013–1035 (1960). This article describes, for the first time, the alteration coined as the ‘Philadelphia chromosome’, the prototype of genetic defects linked to cancer.
Rowley, J. D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290–293 (1973).
doi: 10.1038/243290a0
Kloetzer, W. et al. The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology 140, 230–238 (1985).
doi: 10.1016/0042-6822(85)90361-7
Shtivelman, E., Lifshitz, B., Gale, R. P. & Canaani, E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315, 550–554 (1985).
doi: 10.1038/315550a0
Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561–566 (1996).
doi: 10.1038/nm0596-561
Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001). This publication presents clinical phase I data for imatinib in CML.
doi: 10.1056/NEJM200104053441401
Braun, T. P., Eide, C. A. & Druker, B. J. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell 37, 530–542 (2020).
doi: 10.1016/j.ccell.2020.03.006
Westin, J. R., Kantarjian, H. & Kurzrock, R. Treatment of chronic myelogenous leukemia as a paradigm for solid tumors: how targeted agents in newly diagnosed disease transformed outcomes. Am. Soc. Clin. Oncol. Educ. Book https://doi.org/10.14694/EdBook_AM.2012.32.60 (2012).
doi: 10.14694/EdBook_AM.2012.32.60
Cohen, P., Cross, D. & Jänne, P. A. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat. Rev. Drug Discov. 20, 551–569 (2021).
doi: 10.1038/s41573-021-00195-4
Drilon, A. et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N. Engl. J. Med. 383, 813–824 (2020).
doi: 10.1056/NEJMoa2005653
Drilon, A. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med. 378, 731–739 (2018).
doi: 10.1056/NEJMoa1714448
Shaw, A. T. et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N. Engl. J. Med. 383, 2018–2029 (2020).
doi: 10.1056/NEJMoa2027187
Soria, J.-C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113–125 (2018).
doi: 10.1056/NEJMoa1713137
Shaw, A. T. et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370, 1189–1197 (2014).
doi: 10.1056/NEJMoa1311107
Sawyers, C. L. et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99, 3530–3539 (2002).
doi: 10.1182/blood.V99.10.3530
Gerstung, M. et al. The evolutionary history of 2658 cancers. Nature 578, 122–128 (2020).
doi: 10.1038/s41586-019-1907-7
Christie, A. And Then There Were None (Harper-Collins, 2008).
Vogelstein, B. & Kinzler, K. W. The path to cancer — three strikes and you’re out. N. Engl. J. Med. 373, 1895–1898 (2015).
doi: 10.1056/NEJMp1508811
Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759–767 (1990). This is a comprehensive review of the genetic model of colorectal tumorigenesis.
doi: 10.1016/0092-8674(90)90186-I
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
doi: 10.1016/S0092-8674(00)81683-9
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
doi: 10.1016/j.cell.2011.02.013
Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022).
doi: 10.1158/2159-8290.CD-21-1059
Ding, L. et al. Perspective on oncogenic processes at the end of the beginning of cancer genomics. Cell 173, 305–320 (2018).
doi: 10.1016/j.cell.2018.03.033
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).
doi: 10.1038/s41586-020-1969-6
Kato, S., Lippman, S. M., Flaherty, K. T. & Kurzrock, R. The conundrum of genetic “drivers” in benign conditions. J. Natl Cancer Inst. 108, djw036 (2016).
doi: 10.1093/jnci/djw036
Adashek, J. J., Kato, S., Lippman, S. M. & Kurzrock, R. The paradox of cancer genes in non-malignant conditions: implications for precision medicine. Genome Med. 12, 16 (2020).
doi: 10.1186/s13073-020-0714-y
Anglesio, M. S. et al. Cancer-associated mutations in endometriosis without cancer. N. Engl. J. Med. 376, 1835–1848 (2017).
doi: 10.1056/NEJMoa1614814
Yamanishi, Y. et al. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc. Natl Acad. Sci. USA 99, 10025–10030 (2002).
doi: 10.1073/pnas.152333199
Angelo, L. S., Talpaz, M. & Kurzrock, R. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Res. 62, 932–940 (2002).
Zhang, T. et al. p53 predominantly regulates IL-6 production and suppresses synovial inflammation in fibroblast-like synoviocytes and adjuvant-induced arthritis. Arthritis Res. Ther. 18, 271 (2016).
doi: 10.1186/s13075-016-1161-4
Hlevnjak, M. et al. CATCH: a prospective precision oncology trial in metastatic breast cancer. JCO Precis. Oncol. 5, 676–686 (2021).
doi: 10.1200/PO.20.00248
Horak, P. et al. Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov. 11, 2780–2795 (2021).
doi: 10.1158/2159-8290.CD-21-0126
van Tilburg, C. M. et al. The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets. Cancer Discov. 11, 2764–2779 (2021). Along with Hlevnjak et al. (2021) and Horak et al. (2021), this study presents convincing prospective data for molecularly informed targeted therapies, showing that precision oncology generates a real-world benefit for patients with cancer.
doi: 10.1158/2159-8290.CD-21-0094
Martincorena, I. & Campbell, P. J. Somatic mutation in cancer and normal cells. Science 349, 1483–1489 (2015).
doi: 10.1126/science.aab4082
Olafsson, S. et al. Somatic evolution in non-neoplastic IBD-affected colon. Cell 182, 672–684 (2020).
doi: 10.1016/j.cell.2020.06.036
Kumar, R., Angelini, S., Snellman, E. & Hemminki, K. BRAF mutations are common somatic events in melanocytic nevi. J. Invest. Dermatol. 122, 342–348 (2004).
doi: 10.1046/j.0022-202X.2004.22225.x
Allred, D. C. et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum. Pathol. 23, 974–979 (1992).
doi: 10.1016/0046-8177(92)90257-4
Rakovitch, E. et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br. J. Cancer 106, 1160–1165 (2012).
doi: 10.1038/bjc.2012.41
Williams, K. E. et al. Molecular phenotypes of DCIS predict overall and invasive recurrence. Ann. Oncol. 26, 1019–1025 (2015).
doi: 10.1093/annonc/mdv062
Cappellen, D. et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 23, 18–20 (1999).
doi: 10.1038/12615
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014).
doi: 10.1038/nature12965
Lee-Six, H. et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature 574, 532–537 (2019).
doi: 10.1038/s41586-019-1672-7
Martincorena, I. et al. Somatic mutant clones colonize the human esophagus with age. Science 362, 911–917 (2018).
doi: 10.1126/science.aau3879
Jaiswal, S. & Ebert, B. L. Clonal hematopoiesis in human aging and disease. Science 366, eaan4673 (2019).
doi: 10.1126/science.aan4673
Christie, A. The Man in the Mist (Illustrated London News Company, 1924).
Adashek, J. J., Subbiah, V. & Kurzrock, R. From tissue-agnostic to N-of-one therapies: (r)evolution of the precision paradigm. Trends Cancer Res. 7, 15–28 (2021).
doi: 10.1016/j.trecan.2020.08.009
Turski, M. L. et al. Genomically driven tumors and actionability across histologies: BRAF-mutant cancers as a paradigm. Mol. Cancer Ther. 15, 533–547 (2016).
doi: 10.1158/1535-7163.MCT-15-0643
Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).
doi: 10.1056/NEJMoa1002011
Tiacci, E. et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N. Engl. J. Med. 373, 1733–1747 (2015).
doi: 10.1056/NEJMoa1506583
Falchook, G. S. et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893–1901 (2012).
doi: 10.1016/S0140-6736(12)60398-5
Kopetz, S. et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J. Clin. Oncol. 28 (Suppl. 15), 3534 (2010).
doi: 10.1200/jco.2010.28.15_suppl.3534
Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF
doi: 10.1038/nature10868
Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227–235 (2012).
doi: 10.1158/2159-8290.CD-11-0341
Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N. Engl. J. Med. 381, 1632–1643 (2019).
doi: 10.1056/NEJMoa1908075
Kurzrock, R. et al. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature 325, 631–635 (1987).
doi: 10.1038/325631a0
Christie, A. The Mysterious Affair At Styles (John Lane Company, 1921).
Bailey, C. et al. Tracking cancer evolution through the disease course. Cancer Discov. 11, 916–932 (2021).
doi: 10.1158/2159-8290.CD-20-1559
Ortmann, C. A. et al. Effect of mutation order on myeloproliferative neoplasms. N. Engl. J. Med. 372, 601–612 (2015). This seminal work sheds light on the effects of mutation order on clinical course and therapy response in myeloproliferative neoplasms, providing evidence that clonal evolution has to be considered as a decision-shaping factor in molecular oncology.
doi: 10.1056/NEJMoa1412098
Bozic, I. & Wu, C. J. Delineating the evolutionary dynamics of cancer from theory to reality. Nat. Cancer 1, 580–588 (2020).
doi: 10.1038/s43018-020-0079-6
TRACERx Renal consortium. TRACERx renal: tracking renal cancer evolution through therapy. Nat. Rev. Urol. 14, 575–576 (2017).
doi: 10.1038/nrurol.2017.112
Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
doi: 10.1056/NEJMoa1616288
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012). This study describes spatial intratumoural heterogeneity, implicating a string of consequences for precision oncology approaches.
doi: 10.1056/NEJMoa1113205
Chen, J. et al. Genomic landscape of lung adenocarcinoma in East Asians. Nat. Genet. 52, 177–186 (2020). This work presents data showcasing groundbreaking differences in the genomic and transcriptomic analyses of East Asian patients with lung cancer compared with European patients with lung cancer, serving as an example for the impact of ethnicity in cancer research and therapy.
doi: 10.1038/s41588-019-0569-6
Dearden, S., Stevens, J., Wu, Y.-L. & Blowers, D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann. Oncol. 24, 2371–2376 (2013).
doi: 10.1093/annonc/mdt205
Agboola, A. J. et al. Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast Cancer Res. Treat. 135, 555–569 (2012).
doi: 10.1007/s10549-012-2173-7
Bollig-Fischer, A. et al. Racial diversity of actionable mutations in non-small cell lung cancer. J. Thorac. Oncol. 10, 250–255 (2015).
doi: 10.1097/JTO.0000000000000420
Mao, X. et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res. 70, 5207–5212 (2010).
doi: 10.1158/0008-5472.CAN-09-4074
Kadakia, K. C. & Salem, M. E. Role of immune checkpoint inhibitors in understudied populations. JCO Oncol. Pract. 17, 246–248 (2021).
doi: 10.1200/OP.21.00108
zur Hausen, H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2, 342–350 (2002).
doi: 10.1038/nrc798
Marur, S., D’Souza, G., Westra, W. H. & Forastiere, A. A. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 11, 781–789 (2010).
doi: 10.1016/S1470-2045(10)70017-6
Moody, S. et al. Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence. Nat. Genet. 53, 1553–1563 (2021).
doi: 10.1038/s41588-021-00928-6
Shigematsu, H. et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 97, 339–346 (2005).
doi: 10.1093/jnci/dji055
Knerr, S., Wayman, D. & Bonham, V. L. Inclusion of racial and ethnic minorities in genetic research: advance the spirit by changing the rules? J. Law Med. Ethics 39, 502–512 (2011).
doi: 10.1111/j.1748-720X.2011.00617.x
Spratt, D. E. et al. Racial/ethnic disparities in genomic sequencing. JAMA Oncol. 2, 1070–1074 (2016).
doi: 10.1001/jamaoncol.2016.1854
Li, C. H., Haider, S., Shiah, Y.-J., Thai, K. & Boutros, P. C. Sex differences in cancer driver genes and biomarkers. Cancer Res. 78, 5527–5537 (2018).
doi: 10.1158/0008-5472.CAN-18-0362
Conforti, F. et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol. 19, 737–746 (2018).
doi: 10.1016/S1470-2045(18)30261-4
Wang, S., Zhang, J., He, Z., Wu, K. & Liu, X.-S. The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients’ sex. Int. J. Cancer 145, 2840–2849 (2019).
doi: 10.1002/ijc.32327
Li, C. H. et al. Sex differences in oncogenic mutational processes. Nat. Commun. 11, 4330 (2020).
doi: 10.1038/s41467-020-17359-2
Cullin, N., Azevedo Antunes, C., Straussman, R., Stein-Thoeringer, C. K. & Elinav, E. Microbiome and cancer. Cancer Cell 39, 1317–1341 (2021).
doi: 10.1016/j.ccell.2021.08.006
Fan, Y. & Pedersen, O. Gut microbiota in human metabolic health and disease. Nat. Rev. Microbiol. 19, 55–71 (2021).
doi: 10.1038/s41579-020-0433-9
Nejman, D. et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368, 973–980 (2020).
doi: 10.1126/science.aay9189
Sepich-Poore, G. D. et al. The microbiome and human cancer. Science 371, eabc4552 (2021).
doi: 10.1126/science.abc4552
Pernigoni, N. et al. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science 374, 216–224 (2021).
doi: 10.1126/science.abf8403
Kadosh, E. et al. The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. Nature 586, 133–138 (2020).
doi: 10.1038/s41586-020-2541-0
Greathouse, K. L. et al. Interaction between the microbiome and TP53 in human lung cancer. Genome Biol. 19, 123 (2018).
doi: 10.1186/s13059-018-1501-6
Hayase, E. & Jenq, R. R. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. Genome Med. 13, 107 (2021).
doi: 10.1186/s13073-021-00923-w
Abid, M. B., Shah, N. N., Maatman, T. C. & Hari, P. N. Gut microbiome and CAR-T therapy. Exp. Hematol. Oncol. 8, 31 (2019).
doi: 10.1186/s40164-019-0155-8
Lee, K. A. et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat. Med. 28, 535–544 (2022).
doi: 10.1038/s41591-022-01695-5
Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).
doi: 10.1126/science.aan3706
Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018). Along with Routy et al. (Science, 2018), this study that shows how the composition of the microbiota is able to modulate the response to checkpoint therapy.
doi: 10.1126/science.aan4236
Routy, B. et al. The gut microbiota influences anticancer immunosurveillance and general health. Nat. Rev. Clin. Oncol. 15, 382–396 (2018).
doi: 10.1038/s41571-018-0006-2
Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602–609 (2021). This seminal work shows the reversal of therapy refractiveness using faecal microbiota transplant.
doi: 10.1126/science.abb5920
Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595–602 (2021).
doi: 10.1126/science.abf3363
Elkrief, A. & Routy, B. First clinical proof-of-concept that FMT can overcome resistance to ICIs. Nat. Rev. Clin. Oncol. 18, 325–326 (2021).
doi: 10.1038/s41571-021-00502-3
Christie, A. Murder on the Orient Express (Collins Crime Club, 1934).
Coley, W. B. The treatment of malignat tumors by repeated inoculations of erysipelas. Am. J. Med. Sci. 105, 487–510 (1893).
doi: 10.1097/00000441-189305000-00001
Hernández-Ramírez, R. U., Shiels, M. S., Dubrow, R. & Engels, E. A. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV 4, e495–e504 (2017).
doi: 10.1016/S2352-3018(17)30125-X
Galanina, N., Goodman, A. M., Cohen, P. R., Frampton, G. M. & Kurzrock, R. Successful treatment of HIV-associated Kaposi Sarcoma with immune checkpoint blockade. Cancer Immunol. Res. 6, 1129–1135 (2018).
doi: 10.1158/2326-6066.CIR-18-0121
Mortaz, E. et al. Cancers related to immunodeficiencies: update and perspectives. Front. Immunol. 7, 365 (2016).
doi: 10.3389/fimmu.2016.00365
Marcus, L., Lemery, S. J., Keegan, P. & Pazdur, R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin. Cancer Res. 25, 3753–3758 (2019).
doi: 10.1158/1078-0432.CCR-18-4070
André, T. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med. 383, 2207–2218 (2020).
doi: 10.1056/NEJMoa2017699
Jardim, D. L., Goodman, A., de Melo Gagliato, D. & Kurzrock, R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell 39, 154–173 (2021).
doi: 10.1016/j.ccell.2020.10.001
Kato, S. et al. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. Oncoimmunology 9, 1708065 (2020).
doi: 10.1080/2162402X.2019.1708065
Adashek, J. J., Goloubev, A., Kato, S. & Kurzrock, R. Missing the target in cancer therapy. Nat. Cancer 2, 369–371 (2021).
doi: 10.1038/s43018-021-00204-w
Boichard, A. et al. APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. Oncoimmunology 8, 1550341 (2019).
doi: 10.1080/2162402X.2018.1550341
Pham, T. V. et al. Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy. Mol. Oncol. 14, 1680–1694 (2020).
doi: 10.1002/1878-0261.12748
Goodman, A. M. et al. MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Med. 12, 45 (2020).
doi: 10.1186/s13073-020-00743-4
Zamora, A. E., Crawford, J. C. & Thomas, P. G. Hitting the target: how T cells detect and eliminate tumors. J. Immunol. 200, 392–399 (2018).
doi: 10.4049/jimmunol.1701413
Valpione, S. et al. The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. Nat. Commun. 12, 4098 (2021).
doi: 10.1038/s41467-021-24343-x
Bassani-Sternberg, M. et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat. Commun. 7, 13404 (2016).
doi: 10.1038/ncomms13404
Gibbons, D. L. et al. 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): a phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC. J. Thorac. Oncol. 11, S79 (2016).
doi: 10.1016/S1556-0864(16)30171-X
Felip, E. et al. Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 35 (Suppl. 15), 2502 (2017).
doi: 10.1200/JCO.2017.35.15_suppl.2502
Nasser, N. J., Gorenberg, M. & Agbarya, A. First line Immunotherapy for non-small cell lung cancer. Pharmaceuticals 13, 373 (2020).
doi: 10.3390/ph13110373
Cercek, A. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363–2376 (2022). In this study, the use of PD1 inhibition alone is sufficient to provoke durable responses in locally advanced rectal cancer, illustrating the potential use of checkpoint inhibition as a stand-alone therapy.
doi: 10.1056/NEJMoa2201445
Christie, A. & Fraser, H. The A.B.C. Murders (Harper-Collins, 1936).
Hong, D. S. et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383, 1207–1217 (2020).
doi: 10.1056/NEJMoa1917239
Rodon, J. et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat. Med. 25, 751–758 (2019).
doi: 10.1038/s41591-019-0424-4
Schettini, F. et al. Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer. ESMO Open 6, 100102 (2021).
doi: 10.1016/j.esmoop.2021.100102
Wang, J., Dean, D. C., Hornicek, F. J., Shi, H. & Duan, Z. RNA sequencing (RNA-Seq) and its application in ovarian cancer. Gynecol. Oncol. 152, 194–201 (2019).
doi: 10.1016/j.ygyno.2018.10.002
Rogawski, D. S., Vitanza, N. A., Gauthier, A. C., Ramaswamy, V. & Koschmann, C. Integrating RNA sequencing into neuro-oncology practice. Transl Res. 189, 93–104 (2017).
doi: 10.1016/j.trsl.2017.06.013
Sicklick, J. K. et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat. Med. 25, 744–750 (2019).
doi: 10.1038/s41591-019-0407-5
Kato, S. et al. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-one strategy. Nat. Commun. 11, 4965 (2020).
doi: 10.1038/s41467-020-18613-3
Sicklick, J. K. et al. Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. Genome Med. 13, 155 (2021). The I-PREDICT trial is the first precision medicine trial to provide matched individualized (N-of-1) combination therapies to patients; a higher degree of matching correlated with improvement in all outcome parameters.
doi: 10.1186/s13073-021-00969-w
Jänne, P. A. et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N. Engl. J. Med. 387, 120–131 (2022). Together with Hong et al. (2020), this is important clinical work showing the response of the first KRAS
doi: 10.1056/NEJMoa2204619
Pang, Y. et al. Report of canonical BCR-ABL1 fusion in glioblastoma. JCO Precis. Oncol. 5, 1348–1353 (2021).
doi: 10.1200/PO.20.00519
Schwaederle, M. et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J. Clin. Oncol. 33, 3817–3825 (2015).
doi: 10.1200/JCO.2015.61.5997
Schneider, G., Schmidt-Supprian, M., Rad, R. & Saur, D. Tissue-specific tumorigenesis: context matters. Nat. Rev. Cancer 17, 239–253 (2017).
doi: 10.1038/nrc.2017.5
Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838–857 (2021).
doi: 10.1158/2159-8290.CD-20-1680
Nakamura, Y. et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat. Med. 26, 1859–1864 (2020).
doi: 10.1038/s41591-020-1063-5
Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N. Engl. J. Med. 386, 2261–2272 (2022).
doi: 10.1056/NEJMoa2200075
Malhotra, H., Radich, J. & Garcia-Gonzalez, P. Meeting the needs of CML patients in resource-poor countries. Hematol. Am. Soc. Hematol. Educ. Program. 2019, 433–442 (2019).
doi: 10.1182/hematology.2019000050
Henke, O., Mapendo, P. J., Mkwizu, E. W. & le Coutre, P. Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukaemia patients treated with Imatinib and barriers to access treatment. Ecancermedicalscience 14, 1089 (2020).
doi: 10.3332/ecancer.2020.1089
Nasser, A. et al. Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania. Blood Adv. 5, 1403–1411 (2021).
doi: 10.1182/bloodadvances.2020002973